vs
Side-by-side financial comparison of CACI INTERNATIONAL INC (CACI) and Kenvue (KVUE). Click either name above to swap in a different company.
Kenvue is the larger business by last-quarter revenue ($3.8B vs $2.2B, roughly 1.7× CACI INTERNATIONAL INC). Kenvue runs the higher net margin — 8.7% vs 5.6%, a 3.2% gap on every dollar of revenue. On growth, CACI INTERNATIONAL INC posted the faster year-over-year revenue change (5.7% vs 3.2%). Kenvue produced more free cash flow last quarter ($744.0M vs $138.2M). Over the past eight quarters, CACI INTERNATIONAL INC's revenue compounded faster (7.0% CAGR vs -1.5%).
CACI International Inc is a U.S.-headquartered multinational professional services and information technology firm. It delivers custom technology solutions, cybersecurity services, data analytics, and mission-critical operational support to government defense, intelligence, civilian agencies, and select private sector clients.
Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Combantrin, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey.
CACI vs KVUE — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.2B | $3.8B |
| Net Profit | $123.9M | $330.0M |
| Gross Margin | — | 56.5% |
| Operating Margin | 9.3% | 14.2% |
| Net Margin | 5.6% | 8.7% |
| Revenue YoY | 5.7% | 3.2% |
| Net Profit YoY | 12.7% | 12.6% |
| EPS (diluted) | $5.59 | $0.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.2B | $3.8B | ||
| Q3 25 | $2.3B | $3.8B | ||
| Q2 25 | $2.3B | $3.8B | ||
| Q1 25 | $2.2B | $3.7B | ||
| Q4 24 | $2.1B | $3.7B | ||
| Q3 24 | $2.1B | $3.9B | ||
| Q2 24 | $2.0B | $4.0B | ||
| Q1 24 | $1.9B | $3.9B |
| Q4 25 | $123.9M | $330.0M | ||
| Q3 25 | $124.8M | $398.0M | ||
| Q2 25 | $157.9M | $420.0M | ||
| Q1 25 | $111.9M | $322.0M | ||
| Q4 24 | $109.9M | $293.0M | ||
| Q3 24 | $120.2M | $383.0M | ||
| Q2 24 | $134.7M | $58.0M | ||
| Q1 24 | $115.3M | $296.0M |
| Q4 25 | — | 56.5% | ||
| Q3 25 | — | 59.1% | ||
| Q2 25 | — | 58.9% | ||
| Q1 25 | — | 58.0% | ||
| Q4 24 | — | 56.5% | ||
| Q3 24 | — | 58.5% | ||
| Q2 24 | — | 59.1% | ||
| Q1 24 | — | 57.6% |
| Q4 25 | 9.3% | 14.2% | ||
| Q3 25 | 9.3% | 16.7% | ||
| Q2 25 | 9.0% | 18.0% | ||
| Q1 25 | 9.1% | 14.9% | ||
| Q4 24 | 8.6% | 13.2% | ||
| Q3 24 | 8.7% | 16.8% | ||
| Q2 24 | 9.7% | 3.9% | ||
| Q1 24 | 9.4% | 14.1% |
| Q4 25 | 5.6% | 8.7% | ||
| Q3 25 | 5.5% | 10.6% | ||
| Q2 25 | 6.9% | 10.9% | ||
| Q1 25 | 5.2% | 8.6% | ||
| Q4 24 | 5.2% | 8.0% | ||
| Q3 24 | 5.8% | 9.8% | ||
| Q2 24 | 6.6% | 1.5% | ||
| Q1 24 | 6.0% | 7.6% |
| Q4 25 | $5.59 | $0.16 | ||
| Q3 25 | $5.63 | $0.21 | ||
| Q2 25 | $7.11 | $0.22 | ||
| Q1 25 | $5.00 | $0.17 | ||
| Q4 24 | $4.88 | $0.16 | ||
| Q3 24 | $5.33 | $0.20 | ||
| Q2 24 | $5.97 | $0.03 | ||
| Q1 24 | $5.13 | $0.15 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $423.0M | $1.1B |
| Total DebtLower is stronger | $3.0B | — |
| Stockholders' EquityBook value | $4.1B | $10.8B |
| Total Assets | $8.9B | $27.1B |
| Debt / EquityLower = less leverage | 0.72× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $423.0M | $1.1B | ||
| Q3 25 | $133.0M | $1.1B | ||
| Q2 25 | $106.2M | $1.1B | ||
| Q1 25 | $223.9M | $1.1B | ||
| Q4 24 | $175.7M | $1.1B | ||
| Q3 24 | $440.7M | $1.1B | ||
| Q2 24 | $134.0M | $1.0B | ||
| Q1 24 | $159.2M | $1.2B |
| Q4 25 | $3.0B | — | ||
| Q3 25 | $2.8B | — | ||
| Q2 25 | $2.9B | — | ||
| Q1 25 | $3.1B | — | ||
| Q4 24 | $3.1B | — | ||
| Q3 24 | $1.8B | — | ||
| Q2 24 | $1.5B | — | ||
| Q1 24 | $1.7B | — |
| Q4 25 | $4.1B | $10.8B | ||
| Q3 25 | $4.0B | $10.6B | ||
| Q2 25 | $3.9B | $10.7B | ||
| Q1 25 | $3.7B | $10.1B | ||
| Q4 24 | $3.7B | $9.7B | ||
| Q3 24 | $3.7B | $10.6B | ||
| Q2 24 | $3.5B | $10.2B | ||
| Q1 24 | $3.4B | $10.6B |
| Q4 25 | $8.9B | $27.1B | ||
| Q3 25 | $8.7B | $27.2B | ||
| Q2 25 | $8.6B | $27.1B | ||
| Q1 25 | $8.6B | $26.3B | ||
| Q4 24 | $8.5B | $25.6B | ||
| Q3 24 | $7.2B | $26.9B | ||
| Q2 24 | $6.8B | $26.4B | ||
| Q1 24 | $6.8B | $27.3B |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.69× | — | ||
| Q2 25 | 0.75× | — | ||
| Q1 25 | 0.84× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.50× | — | ||
| Q2 24 | 0.44× | — | ||
| Q1 24 | 0.50× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $154.2M | $854.0M |
| Free Cash FlowOCF − Capex | $138.2M | $744.0M |
| FCF MarginFCF / Revenue | 6.2% | 19.7% |
| Capex IntensityCapex / Revenue | 0.7% | 2.9% |
| Cash ConversionOCF / Net Profit | 1.24× | 2.59× |
| TTM Free Cash FlowTrailing 4 quarters | $634.3M | $1.7B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $154.2M | $854.0M | ||
| Q3 25 | $171.1M | $294.0M | ||
| Q2 25 | $156.0M | $621.0M | ||
| Q1 25 | $230.3M | $428.0M | ||
| Q4 24 | $126.0M | $793.0M | ||
| Q3 24 | $34.7M | $249.0M | ||
| Q2 24 | $157.2M | $440.0M | ||
| Q1 24 | $198.3M | $287.0M |
| Q4 25 | $138.2M | $744.0M | ||
| Q3 25 | $154.1M | $196.0M | ||
| Q2 25 | $128.0M | $533.0M | ||
| Q1 25 | $214.1M | $249.0M | ||
| Q4 24 | $116.1M | $661.0M | ||
| Q3 24 | $23.2M | $190.0M | ||
| Q2 24 | $134.6M | $350.0M | ||
| Q1 24 | $186.6M | $134.0M |
| Q4 25 | 6.2% | 19.7% | ||
| Q3 25 | 6.7% | 5.2% | ||
| Q2 25 | 5.6% | 13.9% | ||
| Q1 25 | 9.9% | 6.7% | ||
| Q4 24 | 5.5% | 18.1% | ||
| Q3 24 | 1.1% | 4.9% | ||
| Q2 24 | 6.6% | 8.8% | ||
| Q1 24 | 9.6% | 3.4% |
| Q4 25 | 0.7% | 2.9% | ||
| Q3 25 | 0.7% | 2.6% | ||
| Q2 25 | 1.2% | 2.3% | ||
| Q1 25 | 0.7% | 4.8% | ||
| Q4 24 | 0.5% | 3.6% | ||
| Q3 24 | 0.6% | 1.5% | ||
| Q2 24 | 1.1% | 2.3% | ||
| Q1 24 | 0.6% | 3.9% |
| Q4 25 | 1.24× | 2.59× | ||
| Q3 25 | 1.37× | 0.74× | ||
| Q2 25 | 0.99× | 1.48× | ||
| Q1 25 | 2.06× | 1.33× | ||
| Q4 24 | 1.15× | 2.71× | ||
| Q3 24 | 0.29× | 0.65× | ||
| Q2 24 | 1.17× | 7.59× | ||
| Q1 24 | 1.72× | 0.97× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CACI
| Service Other | $876.3M | 39% |
| Intelligence Community | $539.0M | 24% |
| Federal Civilian Agencies | $438.6M | 20% |
| Subcontractor | $202.5M | 9% |
| Other | $148.5M | 7% |
| Commercial And Other | $15.2M | 1% |
KVUE
| Self Care | $1.6B | 42% |
| Essential Health | $1.1B | 30% |
| Skin Health And Beauty | $1.0B | 28% |
